Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofipôle SA
23 Décembre 2021 - 7:00AM
Bone Therapeutics SA: Transparency notification received from
S.R.I.W. SA and Sofipôle SA
REGULATED INFORMATION
Article 14 of the Law of 2 May 2007 on disclosure
of major holdings
Gosselies,
Belgium, 23 December
2021, 7am CET – BONE
THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the
cell therapy company addressing unmet medical needs in orthopedics
and other diseases, today announces that it has received a
transparency notification from S.R.I.W. SA (Société Régionale
d’Investissement de Wallonie) dated 14 December 2021. The
transparency notification indicates that the shareholdings held by
its subsidiary, Sofipôle SA (Société Wallonne pour le Financement
des Infrastructures des Pôles de Compétitivité), have passively
crossed below the threshold of 5% as a result of the issuance of
new shares of Bone Therapeutics via the private placement on 2
December 2021. The new shares were delivered to the participating
investors on 7 December 2021.
The notification dated 14 December 2021 contains
the following information:
- Reason for the notification:
Passive crossing of a threshold
- Notification by: A parent
undertaking or a controlling person
- Persons subject to the notification
requirement: S.R.I.W. SA & Sofipôle SA
- Transaction date: 7 December
2021
- Threshold that is crossed: 5%
- Denominator: 21,310,520
- Notified details:
Voting rights |
Previous notification |
After the transaction |
Holders of voting rights |
# of voting
rights |
# of voting
rights |
% of voting
rights |
S.R.I.W. SA |
344,530 |
344,530 |
1.62% |
Sofipôle SA |
778,139 |
862,027 |
4.05% |
Total voting rights held by S.R.I.W and
Sofipôle |
1,122,669 |
1,206,557 |
5.66% |
- Full chain of controlled
undertakings through which the holding is effectively held: The
Walloon Region holds 99.43% of S.R.I.W. SA which controls 60% of
the shares of Sofipôle SA.
- Additional information: This
declaration has been issued as SOFIPOLE SA has crossed below the 5%
threshold.
The notification can be consulted on the website
of Bone Therapeutics, under the heading “Shareholder
Information”.
About Bone Therapeutics
Bone Therapeutics is a leading biotech company
focused on the development of innovative products to address high
unmet needs in orthopedics and other diseases. The Company has a
diversified portfolio of cell therapies at different stages ranging
from pre-clinical programs in immunomodulation to mid stage
clinical development for orthopedic conditions, targeting markets
with large unmet medical needs and limited innovation.
Bone Therapeutics’ core technology is based on
its cutting-edge allogeneic cell and gene therapy platform with
differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs)
which can be stored at the point of use in the hospital. Currently
in pre-clinical development, BT-20, the most recent product
candidate from this technology, targets inflammatory conditions,
while the leading investigational medicinal product, ALLOB,
represents a unique, proprietary approach to bone regeneration,
which turns undifferentiated stromal cells from healthy donors into
bone-forming cells. These cells are produced via the Bone
Therapeutics’ scalable manufacturing process. Following the CTA
approval by regulatory authorities in Europe, the Company has
initiated patient recruitment for the Phase IIb clinical trial with
ALLOB in patients with difficult tibial fractures, using its
optimized production process. ALLOB continues to be evaluated for
other orthopedic indications including spinal fusion, osteotomy,
maxillofacial and dental.
Bone Therapeutics’ cell therapy products are
manufactured to the highest GMP (Good Manufacturing Practices)
standards and are protected by a broad IP (Intellectual Property)
portfolio covering ten patent families as well as knowhow. The
Company is based in the BioPark in Gosselies, Belgium. Further
information is available at www.bonetherapeutics.com.
For further information, please
contact:
Bone Therapeutics SAMiguel
Forte, MD, PhD, Chief Executive OfficerLieve Creten, Chief
Financial Officer ad interimTel: +32 (0)71 12 10
00investorrelations@bonetherapeutics.com
For Belgian Media and Investor
Enquiries:BepublicBert BouserieTel: +32 (0)488 40
44 77bert.bouserie@bepublicgroup.be
International Media Enquiries:Image Box
CommunicationsNeil Hunter / Michelle BoxallTel: +44 (0)20
8943 4685neil.hunter@ibcomms.agency / michelle@ibcomms.agency
For French Media and Investor
Enquiries:NewCap Investor Relations &
Financial CommunicationsPierre Laurent, Louis-Victor
Delouvrier and Arthur RouilléTel: +33 (0)1 44 71 94
94bone@newcap.eu
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company or, as
appropriate, the Company directors’ current expectations and
projections about future events. By their nature, forward-looking
statements involve a number of risks, uncertainties and assumptions
that could cause actual results or events to differ materially from
those expressed or implied by the forward-looking statements. These
risks, uncertainties and assumptions could adversely affect the
outcome and financial effects of the plans and events described
herein. A multitude of factors including, but not limited to,
changes in demand, competition and technology, can cause actual
events, performance or results to differ significantly from any
anticipated development. Forward looking statements contained in
this press release regarding past trends or activities should not
be taken as a representation that such trends or activities will
continue in the future. As a result, the Company expressly
disclaims any obligation or undertaking to release any update or
revisions to any forward-looking statements in this press release
as a result of any change in expectations or any change in events,
conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither the Company nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.